Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has Cancer Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CGIX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 35% a week.
Volatility Over Time: CGIX's weekly volatility has increased from 27% to 35% over the past year.
7 Day Return
1 Year Return
Return vs Industry: CGIX exceeded the US Biotechs industry which returned 44.2% over the past year.
Return vs Market: CGIX matched the US Market which returned 68.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cancer Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StThose Who Purchased Cancer Genetics (NASDAQ:CGIX) Shares Five Years Ago Have A 99% Loss To Show For It
1 year ago | Simply Wall StDo Insiders Own Lots Of Shares In Cancer Genetics, Inc. (NASDAQ:CGIX)?
1 year ago | Simply Wall StDoes The Cancer Genetics, Inc. (NASDAQ:CGIX) Share Price Fall With The Market?
Is Cancer Genetics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CGIX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CGIX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CGIX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CGIX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CGIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CGIX is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (3.9x).
How is Cancer Genetics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cancer Genetics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cancer Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CGIX is currently unprofitable.
Growing Profit Margin: CGIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CGIX is unprofitable, but has reduced losses over the past 5 years at a rate of 30.8% per year.
Accelerating Growth: Unable to compare CGIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.4%).
Return on Equity
High ROE: CGIX has a negative Return on Equity (-87.72%), as it is currently unprofitable.
How is Cancer Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: CGIX's short term assets ($2.8M) do not cover its short term liabilities ($4.8M).
Long Term Liabilities: CGIX's short term assets ($2.8M) exceed its long term liabilities ($134.0K).
Debt to Equity History and Analysis
Debt Level: CGIX is debt free.
Reducing Debt: CGIX has no debt compared to 5 years ago when its debt to equity ratio was 29.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CGIX has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CGIX is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.
What is Cancer Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CGIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CGIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CGIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Roberts (61 yo)
Mr. John A. Roberts, also known as Jay, MBA has been Chief Executive Officer and President of Cancer Genetics, Inc., since April 30, 2018 and is Principal Financial officer and Principal Accounting officer...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD269.03K) is below average for companies of similar size in the US market ($USD513.72K).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
Experienced Management: CGIX's management team is considered experienced (2.4 years average tenure).
Experienced Board: CGIX's board of directors are considered experienced (9.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 403%.
Cancer Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cancer Genetics, Inc.
- Ticker: CGIX
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$48.692m
- Shares outstanding: 10.56m
- Website: https://www.cancergenetics.com
Number of Employees
- Cancer Genetics, Inc.
- 201 Route 17 North
- 2nd Floor
- New Jersey
- United States
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and im...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/31 22:53|
|End of Day Share Price||2021/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.